Immunity Pharma Announces Positive Top Line Results from Phase 2a Trial with IPL344 in ALS Patients

Jerusalem, Israel, January 16, 2024

  • Treatment with IPL344 was well tolerated
  • Changes in the slope of decline in ALSFRS-R demonstrated 48% slower disease progression
...
Read More

Neurofilament (NfL) Reduction Following IPL344 Treatment of ALS Patients

Jerusalem, Israel, December 10, 2023

  • Indication of neurodegeneration slow down following IPL344 treatment

Immunity Pharma, a clinical-stage neurology-focused

...
Read More

Immunity Pharma Announces Promising Interim Results of its Phase 1/2a Study with IPL344 in ALS

Jerusalem, Israel, September 10th 2020

  • Early indications for clinically significant efficacy during IPL344 treatment of ALS patients (ALSFRS-R and SVC)
  • IPL344
...
Read More

Immunity Pharma Announces that Its Novel ALS Treatment was Granted an Orphan Drug Designation by Both the FDA and the European Medicines Agency

Jerusalem, Israel, February 2, 2020

Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today that its novel ALS targeting drug IPL344 was granted an

...
Read More

Immunity Pharma Announces Initiation of a Phase 1/2a Clinical Trial of IPL344 in Patients with ALS

Jerusalem, Israel, August 14 2018

Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today the initiation of a Phase 1/2a clinical trial of IPL344 in

...
Read More

Immunity Pharma Announces Regulatory Approval for Phase 2a Follow-up Study in ALS

Jerusalem, Israel, February 6, 2018

Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today that the Israel's Ministry of Health (MOH) has approved

...
Read More

Immunity Pharma Appoints Mr. Ron Pfeifer as Chairman of the Board

Jerusalem, Israel, October 1, 2017

Immunity Pharma, a privately-held neurology-focused biopharmaceutical company, announced today that Mr. Ron Pfeifer was appointed as the chairman of its

...
Read More

Immunity Pharma Appoints Vice President of Research and Development

Jerusalem, Israel, July 27, 2017

Immunity Pharma, a neurology-focused biopharmaceutical company, announced today that Dr. Ilana Cohen has joined Immunity Pharma as its Vice President of

...
Read More

Immunity Pharma Announces Passing a Two-Year Mark for Treating an ALS Patient with IPL344 under a Compassionate Treatment Protocol

Jerusalem, Israel, December 1, 2016

Immunity Pharma, a neurology-focused biopharmaceutical company, announced today that it has passed a two-year mark for treating an ALS patient with

...
Read More